Europe’s concentrated investment surge in AI technology is sidelining crucial innovation in women’s health, known as femtech. While AI attracts massive venture capital, femtech funding has sharply dropped from €1.89bn in 2021 to €1.1bn in 2022, reflecting broader market shifts and changing investor interests. This disparity threatens to undermine health advancements for half of the population. The capital rush towards AI coincides with a femtech funding crisis influenced by market conditions, reduced investor risk appetite, and sector maturation.
Back
